Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2758-2767

  Zhang, Nan ^a   Sadun, Rebecca E ^a   Arias, Robyn S ^a   Flanagan, Meg L ^a   Sachsman, Suzanne M ^a   Nien, Yu Chih ^a   Khawli, Leslie A ^a,b   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 AGONIST ANTIBODY 2A; HYBRID PROTEIN; PROTEIN ANTIBODY; PROTEIN CD137L; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

4-1BB LIGAND; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; FEMALE; GRANZYMES; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS;

EID: 34249067482     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2343     Document Type: Article

References (55)

1. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006; 29:233-40.
2. O'Carroll KS, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
3. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54.
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
5. Bretscher PA. A two-step, two signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 1999;96:185-90.
6. Sharpe AH, Freeman GJ. The B7-28 superfamily. Nat Rev Immunol 2002;2:116-26.
7. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
8. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998;10:481-9.
9. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-8.
10. Goodwin RG, Din WS, Davis-Smith T, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23:2631-41.
11. Gruss HJ, Duyster J, Herrmann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann Oncol 1996;7:19-26.
12. Kwon BS, Kozak CA, Kim KK, Pickard RT. Genomic organization and chromosomal localization of the T-cell antigen 4-1BB. J Immunol 1994;152:2256-62.
13. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 1989; 86:1963-7.
14. Schwarz H, Valbracht J, Tuckwell J, von Kempis J, Lotz M. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995; 85:1043-52.
15. Alderson MR, Smith CA, Tough TW, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994;24:2219-27.
16. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002;14:275-86.
17. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994;24:367-74.
18. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
19. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 2000;30:392-402.
20. Lee HW, Nam KO, Park SJ, Kwon BS. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol 2003;33:2133-41.
21. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
22. Cooper D, Bansal-Pakala P, Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol 2002;32: 521-9.
23. Diehl L, van Mierlo GJ, den Boer AT, et al. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 2002;168:3755-62.
24. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998;28:1116-21.
25. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
26. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000;101:541-7.
27. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9.
28. + cytolytic T lymphocytes in vivo. Blood 2004;103:177-84.
29. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002;169:4230-6.
30. Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 2004;112:105-16.
31. Zhang H, Merchant MS, Chua KS, et al. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther 2003;2:579-86.
32. - T cells. J Immunol 1997;158:3081-9.
33. + T lymphocytes. J Immunol 2005;174:1898-905.
34. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-8.
35. Starck L, Scholz C, Dorken B, Daniel PT. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP (short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005;35:1257-66.
36. Guinn BA, DeBenedette MA, Watts TH, Berinstein N. L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162: 5003-10.
37. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trail of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50.
38. Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842-8.
39. Epstein AL, Khawli LA, Chen FM, Hu P, Glasky MS, Taylor CR. Tumor necrosis imaging and treatment of solid tumors. In: V. P. Torchilin, editor. Handbook of targeted delivery of imaging agents, Vol. 16, Boca Raton: CRC Press; 1995. p. 259.
40. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005;23:1538-47.
41. Epstein A, Chen D, Ansari A, et al. Radioimmunodetection of necrotic lesions in human tumors using I-131-labeled TNT-1 F(ab′)2 monoclonal antibody. Antibody Immunoconj Radiopharm 1991;4:151-61.
42. Hornick JL, Sharifi J, Khawli LA, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13: 255-68.
43. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res 1999;5:51-60.
44. Li J, Hu P, Khawli LA.Yun A, Epstein AL. chTNT-3/ hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics 2004; 23:1-10.
45. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics 2002;21:421-32.
46. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics 2003;22:197-207.
47. + T-cell depletion. Cancer Res 2003;63:8384-92.
48. Li J, Hu P, Khawli LA, Epstein AL. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother 2003;26:320-31.
49. Flanagan ML, Khawli LA, Hu P, Epstein AL. H60/ TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother 2006;29: 274-83.
50. Unsoeld H, Pircher H. Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 2005;79:4510-3.
51. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 2006;36:468-77.
52. + T cells during primary activation. Int Immunol 2002;14:605-13.
53. Hayashida M, Kawano H, Nakano T, Shiraki K, Suzuki A. Cell death induction by CTL: Perforin/granzyme B system dominantly acts for cell death induction in human hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2000;225:143-50.
54. Yang S, Tsang K-Y, Schlom J. Induction of higher avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 2005;11:5603-15.
55. Lee SJ, Myers L, Muralimohan G, et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004;173:3002-12.